Jeff Bluestone, CEO of the Parker Institute for Cancer Immunotherapy, discusses the institute's research to kick off What's Hot in Bay Area Biotech 2017.
Photo by Michael Drew Photography
Xconomy's Alex Lash speaks with Justin Kao of Helix and Jill Hagenkord of Color during the "You-Omics: Consumers and Health Data" panel.
Photo by Michael Drew Photography
Sarah Gupta, senior medical liaison at uBiome, discusses her company's microbiome test offerings.
Photo by Michael Drew Photography
Dennis Wall, a Stanford professor of pediatrics, explains his research into the role of the microbiome in autism.
Photo by Michael Drew Photography
Karim Dabbagh, chief scientific officer of Second Genome, discusses his company's partnership with Stanford researching the connection between the microbiome and autism.
Photo by Michael Drew Photography
Guardant Health CEO Helmy Eltoukhy (right) speaks with Xconomy's Alex Lash during a session on liquid biopsy.
Photo by Michael Drew Photography
Attendees of What's Hot in Bay Area Biotech 2017 make connections during the networking break.
Photo by Michael Drew Photography
Mark Moasser, a UCSF professor of medicine, provides an overview of liquid biopsy.
Photo by Michael Drew Photography
Kristina Burow, managing director of ARCH Venture Partners, discusses investment trends.
Photo by Michael Drew Photography
Gabe Otte, CEO of Freenome, presents his startup during a Spotlight Talk.
Photo by Michael Drew Photography
Alice Zhang, CEO of Verge Genomics, speaks about her company during a Spotlight Talk.
Photo by Michael Drew Photography
Addicaid CEO Sam Frons talks about her startup's technology while Antoun Nabhan, vice president of development for Pear Therapeutics, looks on.
Photo by Michael Drew Photography
Healthcare is a technologically driven industry and some of those advances are apparent in the products now reaching consumers directly.
From the convenience of home, consumers can order tests that allow them to gain insight about what their genes or their microbiomes can tell them about their health or the risk of developing a particular disease. In the realm of substance abuse, digital technologies are emerging to supplement more traditional approaches to managing addiction. We learned about some the progress of these technologies and more last week during What’s Hot in Bay Area Biotech, Xconomy’s annual look at life science innovation in the San Francisco area.
While some of the technologies discussed during the event are already in the hands of patients and consumers, others will still need years of additional research and testing before they reach the market. For example, blood tests that could detect the early signs of cancer in an apparently healthy person are a decade or more away. In the meantime, we have photos of some of the players involved in developing these technologies and more from our event at UCSF Mission Bay, courtesy of Michael Drew Photography.
We’d like to thank the sponsors, whose support made What’s Hot in Bay Area Biotech possible, including our host, QB3; silver sponsor Biocom; reception sponsors Chrysalis Biomedical Advisors and Next Interactions. And last but not least, a thank you to our audience, who engaged with the speakers and their ideas.
Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at [email protected] Follow @frankvinluan
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace© 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.